A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention

HOST-ASSURE noninferiority trial

Kyung Woo Park, Si Hyuck Kang, Hyun Jae Kang, Bon Kwon Koo, Byoung Eun Park, Kwang Soo Cha, Jay Young Rhew, Hui Kyoung Jeon, Eun Seok Shin, Ju Hyeon Oh, Myung Ho Jeong, Sanghyun Kim, Kyung Kuk Hwang, Junghan Yoon, Sung Yun Lee, Tae Ho Park, Keon Woong Moon, Hyuck Moon Kwon, Seung Ho Hur, Jae Kean Ryu & 4 others Bong Ryul Lee, Yong Whi Park, In Ho Chae, Hyo Soo Kim

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objectives This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI). Background PtCr provides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents. Methods We randomly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel-related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD. Results At 1 year, TLF occurred in 2.9% and 2.9% of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2% and 0% in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352). Conclusions At 1 year, PtCr-EES was noninferior to CoCr-ZES in all-comers receiving PCI. Although LSD was observed only in PtCr-EES, both the stent length ratio and the frequency of LSD were not significantly different between the 2 stent types, and PtCr-EES was not associated with adverse clinical outcomes. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST-ASSURE]; NCT01267734).

Original languageEnglish
Pages (from-to)2805-2816
Number of pages12
JournalJournal of the American College of Cardiology
Volume63
Issue number25 PART A
DOIs
Publication statusPublished - 2014 Jul 1

Fingerprint

Chromium
Percutaneous Coronary Intervention
Cobalt
Platinum
Stents
Everolimus
zotarolimus
Drug-Eluting Stents
Chromium Alloys

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Park, Kyung Woo ; Kang, Si Hyuck ; Kang, Hyun Jae ; Koo, Bon Kwon ; Park, Byoung Eun ; Cha, Kwang Soo ; Rhew, Jay Young ; Jeon, Hui Kyoung ; Shin, Eun Seok ; Oh, Ju Hyeon ; Jeong, Myung Ho ; Kim, Sanghyun ; Hwang, Kyung Kuk ; Yoon, Junghan ; Lee, Sung Yun ; Park, Tae Ho ; Moon, Keon Woong ; Kwon, Hyuck Moon ; Hur, Seung Ho ; Ryu, Jae Kean ; Lee, Bong Ryul ; Park, Yong Whi ; Chae, In Ho ; Kim, Hyo Soo. / A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention : HOST-ASSURE noninferiority trial. In: Journal of the American College of Cardiology. 2014 ; Vol. 63, No. 25 PART A. pp. 2805-2816.
@article{da66e3cd6c4f4b2bbbe03275dc08dcb3,
title = "A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE noninferiority trial",
abstract = "Objectives This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI). Background PtCr provides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents. Methods We randomly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel-related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD. Results At 1 year, TLF occurred in 2.9{\%} and 2.9{\%} of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2{\%} and 0{\%} in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352). Conclusions At 1 year, PtCr-EES was noninferior to CoCr-ZES in all-comers receiving PCI. Although LSD was observed only in PtCr-EES, both the stent length ratio and the frequency of LSD were not significantly different between the 2 stent types, and PtCr-EES was not associated with adverse clinical outcomes. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST-ASSURE]; NCT01267734).",
author = "Park, {Kyung Woo} and Kang, {Si Hyuck} and Kang, {Hyun Jae} and Koo, {Bon Kwon} and Park, {Byoung Eun} and Cha, {Kwang Soo} and Rhew, {Jay Young} and Jeon, {Hui Kyoung} and Shin, {Eun Seok} and Oh, {Ju Hyeon} and Jeong, {Myung Ho} and Sanghyun Kim and Hwang, {Kyung Kuk} and Junghan Yoon and Lee, {Sung Yun} and Park, {Tae Ho} and Moon, {Keon Woong} and Kwon, {Hyuck Moon} and Hur, {Seung Ho} and Ryu, {Jae Kean} and Lee, {Bong Ryul} and Park, {Yong Whi} and Chae, {In Ho} and Kim, {Hyo Soo}",
year = "2014",
month = "7",
day = "1",
doi = "10.1016/j.jacc.2014.04.013",
language = "English",
volume = "63",
pages = "2805--2816",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "25 PART A",

}

Park, KW, Kang, SH, Kang, HJ, Koo, BK, Park, BE, Cha, KS, Rhew, JY, Jeon, HK, Shin, ES, Oh, JH, Jeong, MH, Kim, S, Hwang, KK, Yoon, J, Lee, SY, Park, TH, Moon, KW, Kwon, HM, Hur, SH, Ryu, JK, Lee, BR, Park, YW, Chae, IH & Kim, HS 2014, 'A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE noninferiority trial', Journal of the American College of Cardiology, vol. 63, no. 25 PART A, pp. 2805-2816. https://doi.org/10.1016/j.jacc.2014.04.013

A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention : HOST-ASSURE noninferiority trial. / Park, Kyung Woo; Kang, Si Hyuck; Kang, Hyun Jae; Koo, Bon Kwon; Park, Byoung Eun; Cha, Kwang Soo; Rhew, Jay Young; Jeon, Hui Kyoung; Shin, Eun Seok; Oh, Ju Hyeon; Jeong, Myung Ho; Kim, Sanghyun; Hwang, Kyung Kuk; Yoon, Junghan; Lee, Sung Yun; Park, Tae Ho; Moon, Keon Woong; Kwon, Hyuck Moon; Hur, Seung Ho; Ryu, Jae Kean; Lee, Bong Ryul; Park, Yong Whi; Chae, In Ho; Kim, Hyo Soo.

In: Journal of the American College of Cardiology, Vol. 63, No. 25 PART A, 01.07.2014, p. 2805-2816.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention

T2 - HOST-ASSURE noninferiority trial

AU - Park, Kyung Woo

AU - Kang, Si Hyuck

AU - Kang, Hyun Jae

AU - Koo, Bon Kwon

AU - Park, Byoung Eun

AU - Cha, Kwang Soo

AU - Rhew, Jay Young

AU - Jeon, Hui Kyoung

AU - Shin, Eun Seok

AU - Oh, Ju Hyeon

AU - Jeong, Myung Ho

AU - Kim, Sanghyun

AU - Hwang, Kyung Kuk

AU - Yoon, Junghan

AU - Lee, Sung Yun

AU - Park, Tae Ho

AU - Moon, Keon Woong

AU - Kwon, Hyuck Moon

AU - Hur, Seung Ho

AU - Ryu, Jae Kean

AU - Lee, Bong Ryul

AU - Park, Yong Whi

AU - Chae, In Ho

AU - Kim, Hyo Soo

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Objectives This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI). Background PtCr provides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents. Methods We randomly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel-related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD. Results At 1 year, TLF occurred in 2.9% and 2.9% of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2% and 0% in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352). Conclusions At 1 year, PtCr-EES was noninferior to CoCr-ZES in all-comers receiving PCI. Although LSD was observed only in PtCr-EES, both the stent length ratio and the frequency of LSD were not significantly different between the 2 stent types, and PtCr-EES was not associated with adverse clinical outcomes. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST-ASSURE]; NCT01267734).

AB - Objectives This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI). Background PtCr provides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents. Methods We randomly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel-related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD. Results At 1 year, TLF occurred in 2.9% and 2.9% of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2% and 0% in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352). Conclusions At 1 year, PtCr-EES was noninferior to CoCr-ZES in all-comers receiving PCI. Although LSD was observed only in PtCr-EES, both the stent length ratio and the frequency of LSD were not significantly different between the 2 stent types, and PtCr-EES was not associated with adverse clinical outcomes. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST-ASSURE]; NCT01267734).

UR - http://www.scopus.com/inward/record.url?scp=84903292699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903292699&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.04.013

DO - 10.1016/j.jacc.2014.04.013

M3 - Article

VL - 63

SP - 2805

EP - 2816

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 25 PART A

ER -